German industry blasts medtech aids tender
This article was originally published in Clinica
A tender for medtech aids submitted by Germany's AOK Hessen sickness insurance fund has drawn criticism from the industry as being price-oriented only. Under the 2007 healthcare reform law, which was designed to increase competition among sickness insurance funds, theses issue tenders for medtech aid supplies. Developments since the April 1 entry into force of the law have been watched closely by Berlin-based BVMed industry association, whose specially-set up decubitus working group said last week that the AOK's tender, for anti-decubitus systems "reduces the selection of such products to mere price alone". The tender closed on February 14.
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.